At 1 year, patients randomized to Rezūm showed a 4.6-point greater improvement on the IPSS symptom score compared with those escalated to combination therapy.
Jean-Nicolas Cornu, MD, PhD, FEBU
Advertisement
Articles by Jean-Nicolas Cornu, MD, PhD, FEBU
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves Titan Prime Inflatable Penile Prosthesis
2
Phase 1 AcTION trial establishes RP2D for 225Ac-PSMA-617
3
FDA approves cefepime and zidebactam for complicated UTI
4
Enzalutamide associated with greater cognitive decline than darolutamide in advanced prostate cancer
5